Celgene Corp (NASDAQ:CELG) was unchanged in Friday’s after-market and the biotech company confirmed the U.S. Food and Drug Administration has approved the company’s psoriatic arthritis treatment, the first of its kind in this country. The drug will be marketed commercially as Otezla. According to the company, the drug works differently than other approved therapies through the intracellular inhibition of phosphodiesterase 4, an enzyme that plays … Continue reading After Hours Movers: NASDAQ:CELG, NASDAQ:LAMR, NYSEMKT:FRD

NovaBay Pharmaceuticals (NYSEMKT:NBY) is lower in late trading after the clinical-stage biopharmaceutical company said late Wednesday that it intends to offer shares of its common stock and warrants in an underwritten public offering. Shares are down 8.73% at $1.15, with a 52-week range of $0.76 – $2.03. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, … Continue reading NovaBay Pharmaceuticals Tumbles 9% in After Hours; Guess (GES) Down as Well